



## **INGENUITY SYSTEMS TO INTEGRATE SPOTFIRE ANALYTICS, BECOMES LATEST SPOTFIRE PARTNER IN LIFE SCIENCES MARKET**

**Ingenuity Systems integrates Spotfire to enable life sciences customers  
to translate new insights into market advantages in drug discovery**

**SOMERVILLE, MA, and REDWOOD CITY, CA – April 5, 2006** – Spotfire and Ingenuity Systems today announced a collaboration to establish integration between Spotfire's DecisionSite® and Ingenuity Pathways Analysis which enables a streamlined workflow between applications to ultimately help mutual customers expedite decision-making in drug discovery research.

"Our customers have made significant investments in data centric information technology. However, they lack the analytical tools that can be broadly deployed among researchers to quickly reveal comprehensive and actionable information," said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems. "Integrating with Spotfire analytics gives researchers the premium experience for interacting with data to achieve a marketplace advantage."

The integration between Ingenuity Pathway Analysis and Spotfire enables researchers to become organizational *difference-makers*. Difference-makers uncover hidden insights, sift through scenarios, and to respond to new market events by translating quantitative information to business response. Through the integration, researchers can combine experimental and biological data for faster drug discovery.

"Life sciences companies are finding that their existing IT investments do not facilitate rapid insights or response to data," said Christian Marcazzo, Senior Director of Life Sciences marketing at Spotfire. "By integrating with Ingenuity Pathways Analysis, researchers can now interact with data in an intuitive fashion, allowing them to quickly arrive at decisions and take action earlier."

### **About Ingenuity's IPA**

Ingenuity Pathways Analysis (IPA) is a web-delivered software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.

---

### **About Spotfire, Inc.**

For thousands of business professionals faced with day-to-day decisions, Spotfire analytics offers the platinum user experience for visually interacting with information. Distinguished by its intuitive ease and analytic power, Spotfire software rapidly reveals unseen threats and illuminates new opportunities, creating significant economic value. Spotfire's customers include industry leaders among the Global 2000 that have deployed

Spotfire analytics to gain an information advantage over their competitors. For more information, visit <http://www.spotfire.com>.

### **About Ingenuity Systems**

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. For more information, visit [www.ingenuity.com](http://www.ingenuity.com)

###

*Spotfire and DecisionSite are registered trademarks of Spotfire, Inc. Other company or product names may be the trademarks of their respective owners.*

### **Editorial Contact:**

For Spotfire:

Amy Groden

617-702-1710

[amy.groden@spotfire.com](mailto:amy.groden@spotfire.com)

For Ingenuity Systems:

Heidi Bullock

+1. 650.381.5150

[hbullock@ingenuity.com](mailto:hbullock@ingenuity.com)